Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ C4496396!4496396!25825981     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncotarget 2015 ; 6 (12): 9766-80 Nephropedia Template TP {{tp|p=25825981|t=2015. EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF |pdf=|usr=}}{{25825981}} gab.com Text EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=25825981 #FOAvip EMMPRIN/CD147 is mainly known for its protease inducing function but a role in promoting tumor angiogenesis has also been demonstrated. This study provides evidence that EMMPRIN is a new coreceptor for the VEGFR-2 tyrosine kinase receptor in both endothelial and tumor cells, as it directly interacts with it and regulates its activation by its VEGF ligand, signalling and functional consequences both in vitro and in vivo. Computational docking analyses and mutagenesis studies identified a molecular binding site in the extracellular domain of EMMPRIN located close to the cell membrane and containing the amino acids 195/199. EMMPRIN is overexpressed in cancer and hence is able to further potentiate VEGFR-2 activation, suggesting that a combinatory therapy of an antiangiogenic drug together with an inhibitor of EMMPRIN/VEGFR-2 interaction may have a greater impact on inhibiting angiogenesis and malignancy. Twit Text FOAVip EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=25825981 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25825981 #FOAvip English Wikipedia <ref>{{Cite pmid|25825981}}</ref> EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF #MMPMID25825981 Khayati F; Pérez-Cano L; Maouche K; Sadoux A; Boutalbi Z; Podgorniak MP; Maskos U; Setterblad N; Janin A; Calvo F; Lebbé C; Menashi S; Fernandez-Recio J; Mourah S Oncotarget 2015[Apr]; 6 (12): 9766-80 PMID25825981show ga EMMPRIN/CD147 is mainly known for its protease inducing function but a role in promoting tumor angiogenesis has also been demonstrated. This study provides evidence that EMMPRIN is a new coreceptor for the VEGFR-2 tyrosine kinase receptor in both endothelial and tumor cells, as it directly interacts with it and regulates its activation by its VEGF ligand, signalling and functional consequences both in vitro and in vivo. Computational docking analyses and mutagenesis studies identified a molecular binding site in the extracellular domain of EMMPRIN located close to the cell membrane and containing the amino acids 195/199. EMMPRIN is overexpressed in cancer and hence is able to further potentiate VEGFR-2 activation, suggesting that a combinatory therapy of an antiangiogenic drug together with an inhibitor of EMMPRIN/VEGFR-2 interaction may have a greater impact on inhibiting angiogenesis and malignancy. äEMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activatio(epmc).pdf DeepDyve Pubget Overpricing